OncoMatch/Blood Cancer — Myelodysplastic (MDS)/SF3B1

Blood Cancer — Myelodysplastic (MDS)SF3B1 Clinical Trials

SF3B1 mutations occur in approximately 25–30% of MDS, are strongly associated with the ring sideroblast morphology, and define a relatively favorable-risk subgroup. Luspatercept, an erythroid maturation agent, is FDA-approved for SF3B1-mutant MDS with ring sideroblasts. Trials investigate luspatercept combinations, novel splicing modulators, and early-intervention strategies in SF3B1-mutant low-risk MDS.